XOMA (NASDAQ:XOMA) Cut to “Sell” at StockNews.com

XOMA (NASDAQ:XOMA) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Separately, HC Wainwright reiterated a “buy” rating and set a $123.00 price objective on shares of XOMA in a research note on Tuesday.

XOMA Stock Performance

NASDAQ:XOMA opened at $25.67 on Wednesday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The stock has a 50-day simple moving average of $29.28 and a two-hundred day simple moving average of $27.95. The firm has a market capitalization of $302.47 million, a PE ratio of -7.38 and a beta of 0.92. XOMA has a 52-week low of $18.57 and a 52-week high of $35.00.

Insiders Place Their Bets

In other XOMA news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the transaction, the chief executive officer now directly owns 34,979 shares in the company, valued at $1,047,621.05. This represents a 38.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 7.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On XOMA

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets grew its holdings in XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares in the last quarter. Rhumbline Advisers boosted its position in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 1,334 shares during the last quarter. Barclays PLC grew its holdings in shares of XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares in the last quarter. Ellsworth Advisors LLC bought a new stake in XOMA in the third quarter worth $516,000. Finally, Bank of New York Mellon Corp raised its stake in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.